GC Cell Presents GCC2005 Phase 1a Progress
Predicted impact: Low
Phase 1a progress update repeats trial news already covered; restructuring risk was reported earlier.
GC Cell지씨셀
144510 · KOSDAQ · ₩144510 · 지씨셀
₩10,470▼ ₩2,480 (19.15%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −54.28%
- Market cap
- ₩165B
- Enterprise value
- ₩246B
- P/E
- —
- P/B
- 0.9×
- Dividend yield
- 0.0%
- ROE
- −132.8%
- Net margin
- −152.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−63.2% from the high
₩10,430Today: ₩10,430 – ₩11,780₩28,450
Returns
- 1W−24.6%
- 1M−27.3%
- 3M−18.3%
- 6M−57.1%
- YTD−57.9%
- 1Y−54.3%
- Volume today
- 340,615
- 13.7× the 20-day average
- Traded today
- ₩3.7B
- Listed shares
- 15,800,344
- EPS (12 months)
- −₩15,594
- Earnings yield −148.9%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
−19.2% on Oct 28, 2026. Trading value 10.5× its normal.
GC Cell shares fell sharply after its US partner Ativa halted development of an NK cell therapy and is reviewing its business restructuring. Earlier the company presented Phase 1a progress data for its GCC2005 treatment.
AI summary of the news and filings linked. It can be wrong; check them.
- GC Cell shares plunge as US partner halts NK therapy development… Ativa to undergo restructuring (Chosun Biz)
- Ativa halts NK drug development, GC Cell plunges; business restructuring under review (Chosun Biz)
- GC Cell falls 9% after affiliate halts clinical trial [Why Bio] (Seoul Economic Daily)
- GC Cell Presents GCC2005 Phase 1a Progress (Business Korea)
- • Foreign investors sold a net ₩800M that day
- • Buzz 74 on JONBUR: heavy trading
Possible reasons, not certainties. Not financial advice.
Signals
Buzzing- BuzzHighBuzz 74: heavy trading.
- SentimentNegativeNews: Partner halted a therapy program and shares fell about 9%, with restructuring under review. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-25.5% over the last month; the price is below its 20-day average.
- News impactSome6 news items and filings in two weeks; 0 rated high impact, 3 medium.
Signals describe activity, not recommendations. Not financial advice.
GC Cell stock overview
GC Cell (지씨셀, KRX: 144510) is listed on KOSDAQ, in the Business services sector. Korean cell therapy developer that researches, manufactures, and commercializes cell and gene therapies, offering integrated solutions from diagnosis to treatment. Its shares closed at ₩10,470 on Oct 28, 2026, down 19.15% on the day, giving it a market value of ₩165B.
Key facts
- Market cap
- ₩165B
- Sector
- Business services
- Latest price change
- −19.15%
- As of
- Oct 28, 2026
- Main business
- Korean cell therapy developer that researches, manufactures, and commercializes cell and gene therapies, offering integrated solutions from diagnosis to treatment.
Quick answers about GC Cell
- What does GC Cell do?
- Korean cell therapy developer that researches, manufactures, and commercializes cell and gene therapies, offering integrated solutions from diagnosis to treatment. Its main businesses are cell therapy products (including CAR-NK and CAR-T candidates), specimen testing services, cord blood banking, bio-logistics with cold chain management, and contract development and manufacturing (CDMO) services. Its main production facility is the Cell Center in Yongin, Gyeonggi Province, and it also operates a manufacturing facility in Tokyo, Japan.
- What is the market cap of GC Cell?
- The market capitalisation of GC Cell was ₩165B at the close on Oct 28, 2026.
- Who are the largest shareholders of GC Cell?
- According to the latest official filings, the largest reported holders are VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (0.80%, as of Jul 31, 2026); VANGUARD DEVELOPED MARKETS INDEX FUND (0.57%, as of Jun 30, 2026); EMERGING MARKETS CORE EQUITY 2 PORTFOLIO (0.29%, as of Jul 31, 2026).
- When is the next earnings report from GC Cell?
- Korean companies rarely announce results dates in advance. Based on when GC Cell filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own GC Cell?
- Yes. The National Pension Service held 0.06% of GC Cell shares as of Dec 31, 2025.
Company profile
Korean cell therapy developer that researches, manufactures, and commercializes cell and gene therapies, offering integrated solutions from diagnosis to treatment. Its main businesses are cell therapy products (including CAR-NK and CAR-T candidates), specimen testing services, cord blood banking, bio-logistics with cold chain management, and contract development and manufacturing (CDMO) services. Its main production facility is the Cell Center in Yongin, Gyeonggi Province, and it also operates a manufacturing facility in Tokyo, Japan.
Written by AI from the company's latest annual report.
- Korean name
- 지씨셀
- Sector
- Business services
- Themes
- Biotech (new drugs)
- CEO
- 원성용, 김재왕
- Founded
- Jun 2011
- Listed
- Jun 2016
- Listed shares
- 15,800,344
- Fiscal year ends
- Month 12
- Website
- www.gclabcell.com
Similar companies
- S-1012750 · ₩3.6T₩95,100−0.21%
- Cheil Worldwide030000 · ₩2.1T₩18,510−2.63%
- Doosan Tesna131970 · ₩2T₩105,500+8.65%
- Lotte Tour Development032350 · ₩844B₩10,590+2.82%
- Soulbrain Holdings036830 · ₩791B₩38,600+2.52%
- Innocean Worldwide214320 · ₩702B₩17,560+1.15%
- Korea Ratings034950 · ₩456B₩100,500−0.30%
- Hanatour Service039130 · ₩436B₩28,150+3.87%
Recent news
GC Cell shares plunge as US partner halts NK therapy development… Ativa to undergo restructuring
Predicted impact: Medium
Same NK drug halt and restructuring already reported; GC Cell drop was 9%.
Ativa halts NK drug development, GC Cell plunges; business restructuring under review
Predicted impact: Medium
Partner halts NK drug development; GC Cell fell sharply, restructuring under review.
Recent filings
See all- Status of Operation of Fair Trade Self-Compliance ProgramSep 15, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Preliminary earnings (consolidated)Jul 30, 2026
- Insider shareholding reportJul 27, 2026
- Insider shareholding reportJul 24, 2026
Titles in Korean until English translations are added.
Also known as: GC Cell / 지씨셀 / 144510 / KRX:144510
Source: KRX statistical information